Walker G S, Peacock M, Aaron J, Robinson P J, Davison A M
Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:125s-130s. doi: 10.1111/j.1365-2265.1977.tb03372.x.
Twenty-seven patients starting regular haemodialysis were treated with a 1 microgram daily dose of 1alpha-hydroxyvitamin D3 and concurrent aluminium hydroxide therapy to prevent hyperphosphataemia. There was an increase in plasma calcium, but no significant improvement in plasma alkaline phosphatase activity or parathyroid hormone levels. Metastatic calcification progressed but was never a severe clinical problem. Quantitative bone histology showed a significant decrease in resorptive surfaces confirmed radiologically, but there was no significant decrease in forming surfaces. The expected increase in forming surfaces with length of dialysis was however prevented.
27例开始规律血液透析的患者接受每日1微克剂量的1α-羟维生素D3治疗，并同时进行氢氧化铝治疗以预防高磷血症。血浆钙有所升高，但血浆碱性磷酸酶活性或甲状旁腺激素水平无显著改善。转移性钙化有所进展，但从未成为严重的临床问题。定量骨组织学显示，经放射学证实，吸收表面显著减少，但形成表面无显著减少。然而，随着透析时间延长，形成表面预期的增加被阻止。
